文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PSMA-11-PET/CT与胆碱PET/CT引导寡转移性前列腺癌SABR以延迟ADT的比较

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-06-29

PSMA-11-PET组患者PSA更低(中位1.8 vs 4.2 ng/mL,p=0.03),PSA反应持续时间更长(中位34.0 vs 14.7个月,p=0.004),无ADT生存期更长(中位32.7 vs 14.9个月,p=0.01)。

要点

  • PSMA-11-PET可在更低PSA水平(中位1.8 ng/mL)筛选适合SABR的寡转移患者。
  • PSMA-11-PET引导SABR的PSA反应持续时间长于胆碱PET(中位34.0 vs 14.7个月)。
  • PSMA-11-PET组无ADT生存期更长(中位32.7 vs 14.9个月,p=0.01)。

核心结论

  • PSMA-11-PET引导的SABR较胆碱PET引导可延长寡转移性复发性前列腺癌患者的PSA反应持续时间和无ADT生存期。

研究设计与样本

  • 回顾性纳入2012年1月至2017年12月期间基于PSMA-11-PET或胆碱PET诊断的寡转移(≤4个转移灶)复发性前列腺癌(无局部复发)并接受SABR的患者。

主要发现

  • PSMA-11-PET组患者PSA水平更低(中位1.8 vs 4.2 ng/mL,p=0.03)。
  • PSMA-11-PET组PSA反应持续时间显著更长(中位34.0个月(95%CI 16.0-52.0) vs 14.7个月(95%CI 4.7-24.7),p=0.004)。
  • PSMA-11-PET组无ADT生存期显著更长(中位32.7个月(95%CI 20.8-44.5) vs 14.9个月(95%CI 5.7-24.1),p=0.01)。

临床怎么用

  • 对于寡转移性复发性前列腺癌,可优先采用PSMA-11-PET/CT进行分期以筛选适合SABR的患者,从而延迟ADT启动并减少其副作用。

局限性

  • 研究为回顾性设计,PSMA-11-PET组与胆碱PET组样本量差异大(40 vs 10),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with oligometastatic recurrent prostate cancer, standard treatment is androgen deprivation therapy (ADT). However, ADT has many potential side effects that may result in impaired quality of life. Early identification to select patients suitable for stereotactic ablative radiotherapy (SABR) is of utmost importance to prevent or delay start of ADT and its side effects. Because Prostate-Specific Membrane Antigen-11-Positron Emission Tomography (PSMA-11-PET) has a higher sensitivity than choline-PET, we hypothesise that PSMA-11-PET based SABR results in longer response duration and subsequent longer delay in starting ADT than choline-PET. METHODS: Patients with oligometastatic (≤4 metastases) recurrent prostate cancer (with no local recurrence) based on PSMA-11-PET or choline-PET treated with SABR from January 2012 until December 2017 were included. Primary endpoint was ADT-free survival. Secondary endpoints were Prostate Specific Antigen (PSA) response after SABR and time to PSA rise after SABR. RESULTS: Fifty patients (n = 40 PSMA-11-PET and n = 10 choline-PET) with in total 72 lesions were included. Median follow-up was 24.3 months. PSMA-11-PET enabled eligibility of patients with lower PSA levels than choline-PET (median 1.8 versus 4.2 ng/mL, p = 0.03). The PSMA-11-PET group had a significant longer PSA response duration (median 34.0 months (95% confidence interval (CI), 16.0-52.0) versus 14.7 months (95% CI 4.7-24.7), p = 0.004) with a subsequent longer ADT-free survival (median 32.7 months (95% CI, 20.8-44.5) versus 14.9 months (95% CI, 5.7-24.1), p = 0.01). CONCLUSIONS: With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Deijen CL, Vrijenhoek GL, Schaake EE, et al. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer. Clin Transl Radiat Oncol. 2021. PMID: 34278008. doi:10.1016/j.ctro.2021.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。